 |
|
|
| |
Virologic analysis of genotype-1-infected patients treated with once-daily TMC435 during the Optimal Protease inhibitor Enhancement of Response to TherApy (OPERA)-1 study
|
| |
| |
Reported by Jules Levin
AASLD 2010 Nov 2 Boston
O. Lenz,1 L. Vijgen,1 T. Lin,1 M. Peeters,1 G. De Smedt,1 G. Picchio2
1Tibotec, Beerse, Belgium; 2Tibotec Inc., Yardley, PA, USA
Disclosure: all authors are employees of Tibotec.
Corresponding author: Oliver Lenz, Tibotec
Turnhoutseweg 30
2340 Beerse
Belgium
+3214641624
e-mail olenz@its.jnj.com
|
| |
|
|
|
|
|
